Repare Therapeutics Inc Forecast, price target & analysts
Repare Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Repare Therapeutics Inc Classifications & Recommendation:
Repare Therapeutics Inc Price Target
| Target Price | $8.40 |
| Price | $1.20 |
| Potential |
600.00%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Repare Therapeutics Inc 2026 .
The average Repare Therapeutics Inc target price is $8.40.
This is
600.00%
register free of charge
$15.00
1,150.00%
register free of charge
$3.00
150.00%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend Repare Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Repare Therapeutics Inc stock has an average upside potential 2026 of
600.00%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 51.13 | 56.23 |
| 61.22% | 9.97% | |
| EBITDA Margin | -220.63% | -178.91% |
| 1,951.21% | 18.91% | |
| Net Margin | -185.40% | -158.02% |
| 733.29% | 14.77% |
6 Analysts have issued a sales forecast Repare Therapeutics Inc 2024 . The average Repare Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Repare Therapeutics Inc 2024 . The average Repare Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Repare Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Repare Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.23 | -2.09 |
| 223.19% | 6.28% | |
| P/E | negative | |
| EV/Sales | negative |
3 Analysts have issued a Repare Therapeutics Inc forecast for earnings per share. The average Repare Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Repare Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Repare Therapeutics Inc...
Current Repare Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| LifeSci Capital | Locked ➜ Locked | Locked | Dec 13 2024 |
| Stifel | Locked ➜ Locked | Locked | Dec 13 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 08 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 24 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 23 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
LifeSci Capital: Locked ➜ Locked
|
Dec 13 2024 |
|
Locked
Stifel: Locked ➜ Locked
|
Dec 13 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 08 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 24 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Sep 23 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Sep 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
